AURORA, Colo.--(BUSINESS WIRE)--Ocugen receives orphan drug designation for OCU-100 to treat Retinitis Pigmentosa, a rare eye disease, and licenses two biological drug candidates from University of Colorado.
Reported by Business Wire 9 hours ago.
AURORA, Colo.--(BUSINESS WIRE)--Ocugen receives orphan drug designation for OCU-100 to treat Retinitis Pigmentosa, a rare eye disease, and licenses two biological drug candidates from University of Colorado.
Reported by Business Wire 9 hours ago.
